Quick Answer
FibroBiologics, Inc. reported Operating Income Loss of -$16.65 million for the year ending 2025.
- FibroBiologics, Inc. showed a decrease of -21.2% in Operating Income Loss from 2024 to 2025.
- This data is from FibroBiologics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), FibroBiologics, Inc.'s Operating Income Loss has declined by 272.7%.
- Historical annual values: Fiscal year 2025: -$16.65 million | Fiscal year 2024: -$13.74 million | Fiscal year 2023: -$8.89 million | Fiscal year 2022: -$4.47 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: